H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on IDIA stock, giving a Buy rating on March 10.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors relating to Idorsia’s core products and growth trajectory. He highlights the expanding commercial footprint of QUVIVIQ, including a new exclusive distribution agreement in key Middle Eastern markets, as a meaningful driver of future revenue and proof of growing global demand for its insomnia therapy.
At the same time, he points to solid year-over-year sales momentum and management’s outlook for continued QUVIVIQ growth, alongside the longer-term upside from aprocitentan (TRYVIO/JERAYGO) as a second major value pillar. Although he trims the 12‑month price target to CHF5 to reflect reduced mid‑term visibility and higher operating costs, he still sees the risk‑reward profile as attractive, supported by pipeline catalysts such as pediatric insomnia data and the potential for a lucrative North American partnership for aprocitentan.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 22.3% and a 53.98% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Idorsia Ltd, and Emergent Biosolutions.
In another report released on March 10, Kepler Capital also maintained a Buy rating on the stock with a CHF4.50 price target.